Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1995-06-01 (30 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PERIGUEUX (24000), Dordogne
PHARMACIE DU PALAIS : revenue, balance sheet and financial ratios
PHARMACIE DU PALAIS is a French company
founded 30 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PERIGUEUX (24000),
this company of category PME
shows in 2023 a revenue of 1.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU PALAIS (SIREN 401213913)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 150 206 €
N/C
N/C
N/C
963 452 €
989 674 €
980 624 €
970 759 €
Net income
52 280 €
39 754 €
45 161 €
31 316 €
27 578 €
2 326 €
-14 087 €
56 638 €
37 326 €
42 124 €
EBITDA
N/C
N/C
103 390 €
N/C
N/C
N/C
-28 857 €
56 712 €
45 903 €
31 469 €
Net margin
N/C
N/C
3.9%
N/C
N/C
N/C
-1.5%
5.7%
3.8%
4.3%
Revenue and income statement
In 2025, PHARMACIE DU PALAIS generates positive net income of 52 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 42 k€ -> 52 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
52 280 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 37%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
37.05%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
63.368%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
4.06
6.99
5.968
90.724
71.968
82.121
55.031
44.963
40.558
37.05
Financial autonomy
85.776
83.275
86.126
47.973
52.622
50.454
57.603
58.805
61.734
63.368
Repayment capacity
0.05
1.43
-0.065
-22.301
None
None
None
3.507
None
None
Cash flow / Revenue
63.876%
4.029%
-36.207%
-2.528%
None%
None%
None%
8.082%
None%
None%
Sector positioning
Debt ratio
37.052025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Good
In 2025, the debt ratio of PHARMACIE DU PALAIS (37.05) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
63.37%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Good
In 2025, the financial autonomy of PHARMACIE DU PALAIS (63.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.51 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE DU PALAIS (3.51) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 236.26. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
236.256
Liquidity indicators evolution PHARMACIE DU PALAIS
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
234.875
239.335
294.483
342.879
211.478
278.084
243.749
238.889
242.976
236.256
Interest coverage
1.617
3.514
0.67
-2.006
None
None
None
1.88
None
None
Sector positioning
Liquidity ratio
236.262025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good
In 2025, the liquidity ratio of PHARMACIE DU PALAIS (236.26) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
1.88x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE DU PALAIS (1.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 154 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 934 days. Excellent situation: suppliers finance 780 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
154 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
934 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DU PALAIS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
151 904 €
158 008 €
83 806 €
95 613 €
0 €
0 €
0 €
117 436 €
0 €
0 €
Inventory turnover (days)
26
25
20
20
0
0
0
34
0
0
Customer payment term (days)
12
13
2
1
27
27
11
8
139
154
Supplier payment term (days)
37
40
35
35
565
650
636
48
778
934
Positioning of PHARMACIE DU PALAIS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DU PALAIS is estimated at
830 474 €
(range 563 563€ - 1 303 128€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
563k€830k€1303k€
830 474 €Range: 563 563€ - 1 303 128€
NAF 5 année 2025
Valuation method used
Net Income Multiple
52 280 €
×
15.9x
=830 474 €
Range: 563 564€ - 1 303 128€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU PALAIS with other companies in the same sector:
Frequently asked questions about PHARMACIE DU PALAIS
What is the revenue of PHARMACIE DU PALAIS ?
The revenue of PHARMACIE DU PALAIS in 2023 is 1.2 M€.
Is PHARMACIE DU PALAIS profitable?
Yes, PHARMACIE DU PALAIS generated a net profit of 52 k€ in 2025.
Where is the headquarters of PHARMACIE DU PALAIS ?
The headquarters of PHARMACIE DU PALAIS is located in PERIGUEUX (24000), in the department Dordogne.
Where to find the tax return of PHARMACIE DU PALAIS ?
The tax return of PHARMACIE DU PALAIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU PALAIS operate?
PHARMACIE DU PALAIS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart